Background: Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disorder of the oesophagus that has transformed from a rarely recognized condition to one of the most common causes of dysphagia and food impaction in children and young adults. This review provides a comprehensive, clinically oriented overview of EoE for the practicing clinician.Methods: We conducted a narrative review focusing on systematic reviews, meta-analyses, randomized controlled trials and international guidelines published through 2025.Results: EoE pathogenesis involves genetic susceptibility, environmental triggers, epithelial barrier dysfunction and type 2 immune activation. Diagnosis requires clinical symptoms, endoscopic findings and histologic confirmation of >= 15 eosinophils per high-power field. Treatment options include proton pump inhibitors (histologic remission similar to 45%), swallowed topical corticosteroids (similar to 80%-93%), dietary elimination strategies (similar to 60%) and dupilumab (similar to 60%). Without treatment, EoE progresses from inflammatory to fibrostenotic disease, with stricture risk increasing approximately 5% per year of undiagnosed disease.Conclusions: EoE management requires integration of clinical, endoscopic and histologic assessments. Current treatments effectively induce remission in most patients. Future priorities include developing non-invasive monitoring tools and identifying predictors of treatment response.

Eosinophilic esophagitis: From pathophysiology to diagnosis, monitoring and treatment

Federico Caldart;
2026-01-01

Abstract

Background: Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disorder of the oesophagus that has transformed from a rarely recognized condition to one of the most common causes of dysphagia and food impaction in children and young adults. This review provides a comprehensive, clinically oriented overview of EoE for the practicing clinician.Methods: We conducted a narrative review focusing on systematic reviews, meta-analyses, randomized controlled trials and international guidelines published through 2025.Results: EoE pathogenesis involves genetic susceptibility, environmental triggers, epithelial barrier dysfunction and type 2 immune activation. Diagnosis requires clinical symptoms, endoscopic findings and histologic confirmation of >= 15 eosinophils per high-power field. Treatment options include proton pump inhibitors (histologic remission similar to 45%), swallowed topical corticosteroids (similar to 80%-93%), dietary elimination strategies (similar to 60%) and dupilumab (similar to 60%). Without treatment, EoE progresses from inflammatory to fibrostenotic disease, with stricture risk increasing approximately 5% per year of undiagnosed disease.Conclusions: EoE management requires integration of clinical, endoscopic and histologic assessments. Current treatments effectively induce remission in most patients. Future priorities include developing non-invasive monitoring tools and identifying predictors of treatment response.
2026
dupilumab
dysphagia
eosinophilic esophagitis
oesophageal remodelling
topical corticosteroids
type 2 inflammation
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1198847
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact